Cargando…

Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy

BACKGROUND: Associations between candidate genetic variants and treatment outcomes of oxaliplatin, a drug commonly used for colorectal cancer patients, have been reported but not robustly established. This study aimed to validate previously reported prognostic and predictive genetic markers for oxal...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hanla A., Seibold, Petra, Edelmann, Dominic, Benner, Axel, Canzian, Federico, Alwers, Elizabeth, Jansen, Lina, Schneider, Martin, Hoffmeister, Michael, Brenner, Hermann, Chang-Claude, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789680/
https://www.ncbi.nlm.nih.gov/pubmed/34862210
http://dx.doi.org/10.1158/1055-9965.EPI-21-0814
_version_ 1784859007049007104
author Park, Hanla A.
Seibold, Petra
Edelmann, Dominic
Benner, Axel
Canzian, Federico
Alwers, Elizabeth
Jansen, Lina
Schneider, Martin
Hoffmeister, Michael
Brenner, Hermann
Chang-Claude, Jenny
author_facet Park, Hanla A.
Seibold, Petra
Edelmann, Dominic
Benner, Axel
Canzian, Federico
Alwers, Elizabeth
Jansen, Lina
Schneider, Martin
Hoffmeister, Michael
Brenner, Hermann
Chang-Claude, Jenny
author_sort Park, Hanla A.
collection PubMed
description BACKGROUND: Associations between candidate genetic variants and treatment outcomes of oxaliplatin, a drug commonly used for colorectal cancer patients, have been reported but not robustly established. This study aimed to validate previously reported prognostic and predictive genetic markers for oxaliplatin treatment outcomes and evaluate additional putative functional variants. METHODS: Fifty-three SNPs were selected based on previous reports (40 SNPs) or putative function in candidate genes (13 SNPs). We used data from 1,502 patients with stage II–IV colorectal cancer who received primary adjuvant chemotherapy, 37% of whom received oxaliplatin treatment. Multivariable Cox proportional hazards models for overall survival and progression-free survival were applied separately in stage II–III and stage IV patients. For predictive SNPs, differential outcomes according to the type of chemotherapy (oxaliplatin-based vs. others) were evaluated using an interaction term. For prognostic SNPs, the association was assessed solely in patients with oxaliplatin-based treatment. RESULTS: Twelve SNPs were predictive and/or prognostic at P < 0.05 with differential survival based on the type of treatment, in patients with stage II–III (GSTM5-rs11807, ERCC2-rs13181, ERCC2-rs1799793, ERCC5-rs2016073, XPC-rs2228000, P2RX7-rs208294, HMGB1-rs1360485) and in patients with stage IV (GSTM5-rs11807, MNAT1-rs3783819, MNAT1-rs4151330, CXCR1-rs2234671, VEGFA-rs833061, P2RX7-rs2234671). In addition, five novel putative functional SNPs were identified to be predictive (ATP8B3-rs7250872, P2RX7-rs2230911, RPA1-rs5030755, MGMT-rs12917, P2RX7-rs2227963). CONCLUSIONS: Some SNPs yielded prognostic and/or predictive associations significant at P < 0.05, however, none of the associations remained significant after correction for multiple testing. IMPACT: We did not robustly confirm previously reported SNPs despite some suggestive findings but identified further potential predictive SNPs, which warrant further investigation in well-powered studies.
format Online
Article
Text
id pubmed-9789680
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-97896802023-01-05 Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy Park, Hanla A. Seibold, Petra Edelmann, Dominic Benner, Axel Canzian, Federico Alwers, Elizabeth Jansen, Lina Schneider, Martin Hoffmeister, Michael Brenner, Hermann Chang-Claude, Jenny Cancer Epidemiol Biomarkers Prev Research Articles BACKGROUND: Associations between candidate genetic variants and treatment outcomes of oxaliplatin, a drug commonly used for colorectal cancer patients, have been reported but not robustly established. This study aimed to validate previously reported prognostic and predictive genetic markers for oxaliplatin treatment outcomes and evaluate additional putative functional variants. METHODS: Fifty-three SNPs were selected based on previous reports (40 SNPs) or putative function in candidate genes (13 SNPs). We used data from 1,502 patients with stage II–IV colorectal cancer who received primary adjuvant chemotherapy, 37% of whom received oxaliplatin treatment. Multivariable Cox proportional hazards models for overall survival and progression-free survival were applied separately in stage II–III and stage IV patients. For predictive SNPs, differential outcomes according to the type of chemotherapy (oxaliplatin-based vs. others) were evaluated using an interaction term. For prognostic SNPs, the association was assessed solely in patients with oxaliplatin-based treatment. RESULTS: Twelve SNPs were predictive and/or prognostic at P < 0.05 with differential survival based on the type of treatment, in patients with stage II–III (GSTM5-rs11807, ERCC2-rs13181, ERCC2-rs1799793, ERCC5-rs2016073, XPC-rs2228000, P2RX7-rs208294, HMGB1-rs1360485) and in patients with stage IV (GSTM5-rs11807, MNAT1-rs3783819, MNAT1-rs4151330, CXCR1-rs2234671, VEGFA-rs833061, P2RX7-rs2234671). In addition, five novel putative functional SNPs were identified to be predictive (ATP8B3-rs7250872, P2RX7-rs2230911, RPA1-rs5030755, MGMT-rs12917, P2RX7-rs2227963). CONCLUSIONS: Some SNPs yielded prognostic and/or predictive associations significant at P < 0.05, however, none of the associations remained significant after correction for multiple testing. IMPACT: We did not robustly confirm previously reported SNPs despite some suggestive findings but identified further potential predictive SNPs, which warrant further investigation in well-powered studies. American Association for Cancer Research 2022-02 2022-02-07 /pmc/articles/PMC9789680/ /pubmed/34862210 http://dx.doi.org/10.1158/1055-9965.EPI-21-0814 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs International 4.0 License.
spellingShingle Research Articles
Park, Hanla A.
Seibold, Petra
Edelmann, Dominic
Benner, Axel
Canzian, Federico
Alwers, Elizabeth
Jansen, Lina
Schneider, Martin
Hoffmeister, Michael
Brenner, Hermann
Chang-Claude, Jenny
Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy
title Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy
title_full Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy
title_fullStr Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy
title_full_unstemmed Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy
title_short Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy
title_sort validation of genetic markers associated with survival in colorectal cancer patients treated with oxaliplatin-based chemotherapy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789680/
https://www.ncbi.nlm.nih.gov/pubmed/34862210
http://dx.doi.org/10.1158/1055-9965.EPI-21-0814
work_keys_str_mv AT parkhanlaa validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT seiboldpetra validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT edelmanndominic validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT benneraxel validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT canzianfederico validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT alwerselizabeth validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT jansenlina validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT schneidermartin validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT hoffmeistermichael validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT brennerhermann validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy
AT changclaudejenny validationofgeneticmarkersassociatedwithsurvivalincolorectalcancerpatientstreatedwithoxaliplatinbasedchemotherapy